NetraMark Presents Explainable AI at ASCP Meeting

According to a Globe Newswire press release, NetraMark Holdings Inc. announced participation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, May 26 to May 29, 2026. The release states that NetraMark Founder Dr. Joseph Geraci, PhD, will participate in a plenary panel on Thursday, May 28 at 5:30 PM ET, titled "Artificial Intelligence: Understanding the Present and Anticipating the Future" (Globe Newswire). The release also reports that NetraMark will present two scientific posters demonstrating applications of its proprietary NetraAI platform in neuropsychiatric clinical development, and lists Poster W51: Multimodal Identification of Neurobiological Subtypes Associated with Ketamine Response in Treatment-Resistant Depression for Wednesday, May 27 at 11:45 AM ET (Globe Newswire).

Per the Globe Newswire release, the presentations highlight the application of explainable AI to identify clinically meaningful patient subgroups, support predictive enrichment strategies, and generate interpretable insights from complex clinical trial datasets using the NetraAI platform (Globe Newswire). The release includes a quoted remark from Dr. Geraci: "This plenary session addresses one of the most important questions facing AI in clinical development: how to responsibly apply advanced analytical systems to highly heterogeneous clinical datasets" (Globe Newswire).

Explainable-AI approaches and multimodal integration reported in the NetraMark abstracts align with an industry trend of combining clinical, biomarker, and behavioral data to derive stratified responder groups. Companies and academic groups using similar methods commonly focus on model interpretability to make subgroup signals actionable for trial enrichment and regulatory review. For practitioners, work presented as explainable-AI often emphasizes feature attribution, clustering of multimodal signals, and transparent pipelines rather than opaque end-to-end black boxes.

Conference posters and plenary participation provide early visibility into applied methods and datasets even when full code or data are not released. Industry observers use these presentations to gauge reproducibility, potential clinical-readout timelines, and the maturity of methods for integration into trial design. The presence of a plenary panel on AI in psychiatry at ASCP reflects growing attention to both methodological opportunity and data heterogeneity challenges in psychiatric trials.

• •Whether NetraMark posts abstracts, full poster PDFs, or supplementary methods after ASCP, enabling replication or deeper review.
• •Evidence of independent validation of reported subtypes or predictive enrichment strategies in external cohorts.
• •Any technical artifacts or performance metrics disclosed that allow comparison to existing subgroup-identification methods.